Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 8/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421349 | 1.00 | AKR1B1 (1.00) | AKR1B1CA9PTPN1MAPTMEN1 | |
| SCHEMBL1421345 | 1.00 | AKR1B1 (1.00) | AKR1B1CA9PTPN1MAPTMEN1 | |
| SCHEMBL9011343 | 0.92 | AKR1B1 (0.84) | AKR1B1CA9PTPN1MAPT | |
| SCHEMBL9011346 | 0.92 | AKR1B1 (0.84) | AKR1B1CA9PTPN1MAPT | |
| SCHEMBL1905077 | 0.87 | AKR1B1 (0.77) | AKR1B1PTPN1KMT2A | |
| SCHEMBL1905080 | 0.87 | AKR1B1 (0.77) | AKR1B1PTPN1KMT2A | |
| SCHEMBL1905078 | 0.87 | AKR1B1 (0.77) | AKR1B1PTPN1KMT2A | |
| SCHEMBL20534605 | 0.86 | AKR1B1 (1.00) | AKR1B1CA9MAPTMEN1ALDH1A1 | |
| SCHEMBL20534606 | 0.86 | AKR1B1 (1.00) | AKR1B1CA9MAPTMEN1ALDH1A1 | |
| SCHEMBL3804352 | 0.86 | AKR1B1 (0.75) | AKR1B1CA9MAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2296664-A1 | AN INHIBITOR OF ANTI-APOPTOTIC PROTEINS | Burnham Institute for Medical Research (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009129317-A1 | AN INHIBITOR OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-10-22 | — | — | WO | claimed |
| US-20090258914-A1 | Inhibitor of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-10-15 | — | — | US | claimed |
| EP-2296664-A1 | AN INHIBITOR OF ANTI-APOPTOTIC PROTEINS | Burnham Institute for Medical Research (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009129317-A1 | AN INHIBITOR OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090258914-A1 | Inhibitor of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2000018746-A1 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258914-A1 | Inhibitor of Anti-Apoptotic Proteins | BCL2, BAX, API5 | AKR1B1 3846/4885CA9 4680/4885PTPN1 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.